VEGFA rs2010922: Understanding This Common Genetic Variant
The rs2010922 variant is a well-studied genetic change located in the regulatory region of the VEGFA gene. It is primarily associated with variations in circulating levels of the VEGF protein and has been investigated for its potential role in diabetic microvascular complications.
What each genotype means
Baseline VEGF expression
You carry two copies of the G allele (historically designated -634G in research literature). Published association studies link this genotype with baseline levels of vascular endothelial growth factor (VEGFA) expression and average microvascular complication risk in people with diabetes, though findings across different ancestral cohorts remain mixed. This profile reflects common statistical trends and does not predict individual health outcomes.
Carried by approximately 30% to 50% of individuals globally, being most frequent in populations of African and European ancestry.
Intermediate VEGF expression
You carry one copy of the C allele and one copy of the G allele at rs2010922 (often cited as -634G>C). Research shows this heterozygous state is associated with intermediate circulating VEGF levels and modest differences in diabetic microvascular risk profiles, although evidence remains limited and varies by population background. These population-level associations do not constitute a clinical diagnosis or personal risk assessment.
Found in roughly 40% to 50% of individuals across most major continental populations.
Altered VEGF expression
You carry two copies of the C allele at rs2010922 (traditionally noted as -634C/C). Several observational studies correlate this promoter variant genotype with altered transcription efficiency, differences in circulating VEGF concentrations, and potential susceptibility to diabetic microvascular traits like retinopathy or nephropathy, but the overall evidence is limited and non-definitive. Because multiple genetic and lifestyle factors influence vascular health, this variant alone does not determine clinical outcomes.
Carried by roughly 10% to 20% of individuals worldwide, occurring somewhat more frequently in East Asian cohorts.
What is rs2010922?
The variant rs2010922 is a single nucleotide polymorphism (SNP) located within the promoter and 5'-untranslated region (5'-UTR) of the VEGFA gene. In genetic terms, this is often referred to as a -634G>C substitution. Because this variant sits in a regulatory region rather than the protein-coding sequence, it does not change the structure of the protein itself. Instead, it is thought to influence how much of the VEGFA protein is produced by the cell. By altering the regulatory landscape of the gene, this SNP can lead to differences in gene expression levels between individuals. Scientists study these types of variants to understand how subtle changes in our DNA can lead to measurable differences in biological traits, such as the concentration of specific proteins circulating in the bloodstream.
The Role of the VEGFA Gene
The VEGFA gene provides instructions for making a protein called vascular endothelial growth factor A. This protein is a potent signal that stimulates angiogenesis, the process of creating new blood vessels from existing ones. It also plays a critical role in maintaining the health and permeability of blood vessels throughout the body. Because of its central role in blood vessel growth, VEGFA is essential for normal development and wound healing. However, when its expression is dysregulated, it can contribute to various health conditions. For example, excessive VEGF activity is often observed in tumor growth, where it helps supply blood to cancer cells. Conversely, in the context of diabetes, abnormal VEGF signaling is implicated in the development of microvascular complications, such as damage to the small blood vessels in the eyes and kidneys.
Research and Associations
Research into rs2010922 has primarily focused on its association with circulating VEGF levels and its potential impact on diabetic microvascular complications. Studies have observed that this variant may influence the amount of VEGF protein found in the blood. While some research suggests a link between specific VEGFA variants and the risk of developing conditions like diabetic retinopathy, the evidence remains limited and sometimes inconsistent across different study populations. It is important to note that genetic associations are statistical in nature and do not imply a direct cause-and-effect relationship for any single individual. Many factors, including environmental influences, lifestyle, and other genetic markers, contribute to the development of complex diseases. Current scientific consensus suggests that while rs2010922 is a useful marker for research, it should not be used as a standalone tool for predicting individual health outcomes.
What You Can Do With This Information
Understanding your genetic profile can be an interesting way to learn about your biological makeup, but it is important to maintain a realistic perspective on what this information means for your health. Genetic variants like rs2010922 are common and are found in many healthy individuals. They are not diagnostic tools and cannot predict whether you will develop a specific disease. If you are concerned about your risk for diabetes or related vascular complications, the most effective steps involve working with your healthcare provider to monitor clinical markers like blood glucose, blood pressure, and lipid levels. If you are currently taking medications that target VEGF pathways, such as those used for retinal conditions, always discuss your treatment plan and any questions about your genetic results with your clinician or pharmacist. They are the best resources for interpreting how your unique health history interacts with your genetic background.
How common is this variant?
The rs2010922 variant is common globally, with the minor allele frequency typically ranging between 0.30 and 0.45 across major continental populations.
Frequently asked questions
Is rs2010922 a disease-causing mutation?
No, rs2010922 is a common genetic variant, not a disease-causing mutation. It is associated with variations in protein levels, but it does not directly cause disease on its own.
Can I use this SNP to predict my risk of diabetes?
No, this SNP is not a diagnostic tool. Diabetes is a complex condition influenced by many genetic and environmental factors, and this variant alone cannot predict your risk.
Does this variant affect how I respond to medication?
While some medications target the VEGF pathway, there is no standard clinical guidance for using rs2010922 to adjust medication dosing. Always consult your doctor or pharmacist regarding your specific treatment.
Where can I find more information about VEGFA?
You can find reliable information about the VEGFA gene and its functions on resources like MedlinePlus Genetics or the GeneCards database.
Sources & further reading
Educational information only, last refreshed 10/12/2026. Not medical advice — these associations describe population statistics, not individual predictions.
Curious what your genotype is for rs2010922?
Upload a raw DNA file from 23andMe, AncestryDNA, MyHeritage, or FamilyTreeDNA and see this variant — plus thousands more — interpreted in your full report.
Get my report — $29Related variants in VEGFA
A regulatory variant in the VEGFA locus associated with age-related macular degeneration (AMD) risk and response to anti-VEGF therapy; functional studies suggest it influences VEGFA expression in retinal pigment epithelium.
Promoter polymorphism (-2578C/A) regulating vascular endothelial growth factor expression, linked to proliferative diabetic retinopathy and atherosclerosis.
Functional promoter variant in VEGFA influencing angiogenic expression profiles that modulate risk for preeclampsia and recurrent pregnancy loss.
Influences the body's natural levels of Vascular Endothelial Growth Factor.
This polymorphism in the VEGFA gene is studied for its potential impact on the response to anti-VEGF therapy in age-related macular degeneration.
This SNP shows a nominal association with bleeding susceptibility in patients treated with warfarin.